nodes	percent_of_prediction	percent_of_DWPC	metapath
Niflumic Acid—PLA2G4A—Epirubicin—prostate cancer	0.32	0.778	CbGbCtD
Niflumic Acid—PTGS2—prostate cancer	0.245	1	CbGaD
Niflumic Acid—PTGS2—Etoposide—prostate cancer	0.0495	0.12	CbGbCtD
Niflumic Acid—PTGS1—Etoposide—prostate cancer	0.0418	0.102	CbGbCtD
Niflumic Acid—CLCNKA—renal system—prostate cancer	0.0118	0.124	CbGeAlD
Niflumic Acid—CLCNKA—testis—prostate cancer	0.00761	0.0804	CbGeAlD
Niflumic Acid—Ridogrel—TBXAS1—prostate cancer	0.00651	0.587	CrCbGaD
Niflumic Acid—SLC16A7—prostate gland—prostate cancer	0.00575	0.0608	CbGeAlD
Niflumic Acid—PLA2G1B—epithelium—prostate cancer	0.00502	0.053	CbGeAlD
Niflumic Acid—PLA2G1B—renal system—prostate cancer	0.00465	0.0492	CbGeAlD
Niflumic Acid—UGT1A9—renal system—prostate cancer	0.00425	0.045	CbGeAlD
Niflumic Acid—PLA2G4A—prostate gland—prostate cancer	0.00416	0.044	CbGeAlD
Niflumic Acid—SLC16A7—urethra—prostate cancer	0.00385	0.0407	CbGeAlD
Niflumic Acid—SLC16A1—prostate gland—prostate cancer	0.00366	0.0387	CbGeAlD
Niflumic Acid—PLA2G4A—seminal vesicle—prostate cancer	0.00352	0.0372	CbGeAlD
Niflumic Acid—PLA2G1B—testis—prostate cancer	0.00301	0.0318	CbGeAlD
Niflumic Acid—Leflunomide—AHR—prostate cancer	0.00291	0.262	CrCbGaD
Niflumic Acid—PLA2G4A—renal system—prostate cancer	0.00283	0.03	CbGeAlD
Niflumic Acid—PLA2G4A—urethra—prostate cancer	0.00278	0.0294	CbGeAlD
Niflumic Acid—SLC16A1—epithelium—prostate cancer	0.00269	0.0284	CbGeAlD
Niflumic Acid—SLC16A7—testis—prostate cancer	0.00253	0.0268	CbGeAlD
Niflumic Acid—SLC16A1—renal system—prostate cancer	0.00249	0.0264	CbGeAlD
Niflumic Acid—PLA2G4A—bone marrow—prostate cancer	0.00214	0.0227	CbGeAlD
Niflumic Acid—SLC16A7—lymph node—prostate cancer	0.00184	0.0194	CbGeAlD
Niflumic Acid—PLA2G4A—testis—prostate cancer	0.00183	0.0194	CbGeAlD
Niflumic Acid—PTGS1—prostate gland—prostate cancer	0.00164	0.0174	CbGeAlD
Niflumic Acid—SLC16A1—testis—prostate cancer	0.00161	0.017	CbGeAlD
Niflumic Acid—PTGS2—prostate gland—prostate cancer	0.00157	0.0166	CbGeAlD
Niflumic Acid—PLA2G4A—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.00156	0.262	CbGdCrCtD
Niflumic Acid—PTGS1—seminal vesicle—prostate cancer	0.00139	0.0147	CbGeAlD
Niflumic Acid—PLA2G4A—lymph node—prostate cancer	0.00133	0.014	CbGeAlD
Niflumic Acid—PTGS2—seminal vesicle—prostate cancer	0.00133	0.014	CbGeAlD
Niflumic Acid—PLA2G4A—Estradiol—Estramustine—prostate cancer	0.00132	0.223	CbGdCrCtD
Niflumic Acid—PTGS1—epithelium—prostate cancer	0.00121	0.0128	CbGeAlD
Niflumic Acid—SLC16A1—lymph node—prostate cancer	0.00117	0.0124	CbGeAlD
Niflumic Acid—PTGS2—epithelium—prostate cancer	0.00115	0.0122	CbGeAlD
Niflumic Acid—PTGS1—renal system—prostate cancer	0.00112	0.0118	CbGeAlD
Niflumic Acid—PTGS2—renal system—prostate cancer	0.00107	0.0113	CbGeAlD
Niflumic Acid—PLA2G4A—Estradiol—Estrone—prostate cancer	0.00105	0.177	CbGdCrCtD
Niflumic Acid—PTGS2—urethra—prostate cancer	0.00105	0.0111	CbGeAlD
Niflumic Acid—Mefenamic acid—AKR1C3—prostate cancer	0.00102	0.0923	CrCbGaD
Niflumic Acid—PLA2G4A—Estradiol—Conjugated Estrogens—prostate cancer	0.000925	0.156	CbGdCrCtD
Niflumic Acid—PTGS2—bone marrow—prostate cancer	0.000809	0.00855	CbGeAlD
Niflumic Acid—PLA2G4A—Estradiol—Ethinyl Estradiol—prostate cancer	0.000777	0.131	CbGdCrCtD
Niflumic Acid—PTGS1—testis—prostate cancer	0.000723	0.00765	CbGeAlD
Niflumic Acid—PTGS1—lymph node—prostate cancer	0.000524	0.00554	CbGeAlD
Niflumic Acid—PTGS2—lymph node—prostate cancer	0.000501	0.0053	CbGeAlD
Niflumic Acid—Floctafenine—PTGS2—prostate cancer	0.000459	0.0415	CrCbGaD
Niflumic Acid—Mefenamic acid—PTGS2—prostate cancer	0.000179	0.0162	CrCbGaD
Niflumic Acid—PLA2G4A—Dexamethasone—Prednisone—prostate cancer	0.000152	0.0256	CbGdCrCtD
Niflumic Acid—PLA2G4A—Betamethasone—Prednisone—prostate cancer	0.000152	0.0256	CbGdCrCtD
Niflumic Acid—PTGS2—Disease—PRKCZ—prostate cancer	1.39e-05	5.98e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—COMT—prostate cancer	1.39e-05	5.98e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—INS—prostate cancer	1.38e-05	5.97e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—GSTP1—prostate cancer	1.38e-05	5.95e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—AKT1—prostate cancer	1.38e-05	5.93e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ITPR1—prostate cancer	1.37e-05	5.91e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.37e-05	5.9e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CYP2E1—prostate cancer	1.37e-05	5.88e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CALR—prostate cancer	1.36e-05	5.88e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—ITPR1—prostate cancer	1.36e-05	5.86e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—CREBBP—prostate cancer	1.36e-05	5.84e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—MTHFR—prostate cancer	1.35e-05	5.83e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—NQO1—prostate cancer	1.35e-05	5.82e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—FGFR4—prostate cancer	1.34e-05	5.78e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PARP1—prostate cancer	1.34e-05	5.78e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.34e-05	5.76e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—TH—prostate cancer	1.33e-05	5.73e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—HPGDS—prostate cancer	1.33e-05	5.73e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PPARA—prostate cancer	1.33e-05	5.72e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CALCA—prostate cancer	1.33e-05	5.71e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.32e-05	5.7e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP2C19—prostate cancer	1.32e-05	5.69e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CYP3A4—prostate cancer	1.32e-05	5.67e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IGF1R—prostate cancer	1.31e-05	5.65e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—PIK3CA—prostate cancer	1.31e-05	5.65e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.31e-05	5.64e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—JAK2—prostate cancer	1.3e-05	5.6e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CYP1B1—prostate cancer	1.29e-05	5.58e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GSTT1—prostate cancer	1.29e-05	5.56e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—ACHE—prostate cancer	1.29e-05	5.56e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PIK3CD—prostate cancer	1.29e-05	5.54e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—TYMS—prostate cancer	1.28e-05	5.53e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP2A6—prostate cancer	1.27e-05	5.49e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—HSPA1A—prostate cancer	1.27e-05	5.47e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.27e-05	5.47e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—GSTM1—prostate cancer	1.27e-05	5.47e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TP53—prostate cancer	1.27e-05	5.46e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—LPL—prostate cancer	1.26e-05	5.42e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GGT1—prostate cancer	1.25e-05	5.4e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.25e-05	5.39e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—CAV1—prostate cancer	1.25e-05	5.38e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PDGFRB—prostate cancer	1.25e-05	5.37e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—LPL—prostate cancer	1.25e-05	5.37e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—AKR1C3—prostate cancer	1.24e-05	5.34e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—NCOA1—prostate cancer	1.23e-05	5.32e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—PIK3CB—prostate cancer	1.23e-05	5.32e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PRKACB—prostate cancer	1.23e-05	5.31e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP17A1—prostate cancer	1.22e-05	5.26e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CASP9—prostate cancer	1.22e-05	5.25e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CYP19A1—prostate cancer	1.22e-05	5.24e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ITGB3—prostate cancer	1.21e-05	5.23e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—NOS3—prostate cancer	1.21e-05	5.23e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.2e-05	5.19e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—CYP1A1—prostate cancer	1.2e-05	5.18e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—ERCC2—prostate cancer	1.19e-05	5.14e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.19e-05	5.14e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CXCL8—prostate cancer	1.19e-05	5.11e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PRKCQ—prostate cancer	1.18e-05	5.09e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ERBB3—prostate cancer	1.18e-05	5.07e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—FGFR2—prostate cancer	1.18e-05	5.07e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—RXRA—prostate cancer	1.17e-05	5.06e-05	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—PIK3CA—prostate cancer	1.17e-05	5.03e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—NCOA2—prostate cancer	1.16e-05	5.01e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.14e-05	4.92e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PIK3CG—prostate cancer	1.14e-05	4.9e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—IL2—prostate cancer	1.13e-05	4.88e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—COMT—prostate cancer	1.13e-05	4.87e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TERT—prostate cancer	1.13e-05	4.86e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GSTP1—prostate cancer	1.13e-05	4.85e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—FGF10—prostate cancer	1.12e-05	4.83e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—MTHFR—prostate cancer	1.12e-05	4.83e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PIK3CB—prostate cancer	1.12e-05	4.83e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PTGS2—prostate cancer	1.11e-05	4.78e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—SLC5A5—prostate cancer	1.11e-05	4.78e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—ITPR1—prostate cancer	1.11e-05	4.77e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PPARA—prostate cancer	1.1e-05	4.74e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.09e-05	4.69e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP2E1—prostate cancer	1.08e-05	4.67e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—HIF1A—prostate cancer	1.08e-05	4.65e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—INS—prostate cancer	1.08e-05	4.64e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—NQO1—prostate cancer	1.07e-05	4.62e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—AKT1—prostate cancer	1.07e-05	4.61e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TGFBR2—prostate cancer	1.07e-05	4.6e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—TH—prostate cancer	1.06e-05	4.55e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—CREBBP—prostate cancer	1.05e-05	4.54e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—LEP—prostate cancer	1.05e-05	4.54e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—ITPR1—prostate cancer	1.05e-05	4.53e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.05e-05	4.52e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—TYMS—prostate cancer	1.05e-05	4.51e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP3A4—prostate cancer	1.05e-05	4.5e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CAV1—prostate cancer	1.04e-05	4.5e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—GSTM1—prostate cancer	1.03e-05	4.46e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—CAV1—prostate cancer	1.03e-05	4.46e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—KDR—prostate cancer	1.03e-05	4.45e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP1B1—prostate cancer	1.03e-05	4.43e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—LPL—prostate cancer	1.02e-05	4.38e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ESR1—prostate cancer	1.01e-05	4.34e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PIK3CD—prostate cancer	1e-05	4.31e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GGT1—prostate cancer	9.95e-06	4.29e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.89e-06	4.26e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—BAD—prostate cancer	9.82e-06	4.23e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CYP1A1—prostate cancer	9.81e-06	4.23e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—NCOA1—prostate cancer	9.8e-06	4.22e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—ERCC2—prostate cancer	9.73e-06	4.19e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PTEN—prostate cancer	9.69e-06	4.17e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP19A1—prostate cancer	9.66e-06	4.16e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—LPL—prostate cancer	9.63e-06	4.15e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PDGFRB—prostate cancer	9.54e-06	4.11e-05	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—AKT1—prostate cancer	9.54e-06	4.11e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PIK3CG—prostate cancer	9.51e-06	4.1e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—APC—prostate cancer	9.51e-06	4.1e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—NOS3—prostate cancer	9.44e-06	4.07e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PIK3CG—prostate cancer	9.43e-06	4.06e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—EGF—prostate cancer	9.4e-06	4.05e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IRS1—prostate cancer	9.4e-06	4.05e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—RXRA—prostate cancer	9.32e-06	4.02e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—EP300—prostate cancer	9.24e-06	3.98e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—ERCC2—prostate cancer	9.22e-06	3.97e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—MTHFR—prostate cancer	9.15e-06	3.94e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—GSK3B—prostate cancer	9.13e-06	3.93e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	9.07e-06	3.91e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—ERBB3—prostate cancer	9.02e-06	3.89e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—FGFR2—prostate cancer	9.01e-06	3.88e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—INS—prostate cancer	9e-06	3.88e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—COMT—prostate cancer	8.98e-06	3.87e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PPARA—prostate cancer	8.97e-06	3.87e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GSTP1—prostate cancer	8.94e-06	3.85e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—INS—prostate cancer	8.92e-06	3.84e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CREBBP—prostate cancer	8.82e-06	3.8e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—ITPR1—prostate cancer	8.8e-06	3.79e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—CREBBP—prostate cancer	8.74e-06	3.77e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PIK3CB—prostate cancer	8.72e-06	3.76e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IGF1—prostate cancer	8.71e-06	3.75e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MTHFR—prostate cancer	8.67e-06	3.73e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—EGFR—prostate cancer	8.67e-06	3.73e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.65e-06	3.73e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TERT—prostate cancer	8.65e-06	3.72e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PTGS2—prostate cancer	8.64e-06	3.72e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CAV1—prostate cancer	8.44e-06	3.63e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MAP2K1—prostate cancer	8.42e-06	3.63e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PIK3CD—prostate cancer	8.36e-06	3.6e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—TYMS—prostate cancer	8.31e-06	3.58e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PIK3CD—prostate cancer	8.29e-06	3.57e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—SERPINE1—prostate cancer	8.27e-06	3.56e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—HIF1A—prostate cancer	8.27e-06	3.56e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—GSTM1—prostate cancer	8.22e-06	3.54e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—KRAS—prostate cancer	8.19e-06	3.53e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—LPL—prostate cancer	8.06e-06	3.47e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.06e-06	3.47e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—FGF2—prostate cancer	8.01e-06	3.45e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CAV1—prostate cancer	8e-06	3.44e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—NOS3—prostate cancer	7.9e-06	3.4e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—NOS3—prostate cancer	7.83e-06	3.37e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CYP1A1—prostate cancer	7.79e-06	3.36e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—ERCC2—prostate cancer	7.72e-06	3.33e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PIK3CG—prostate cancer	7.68e-06	3.31e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—JAK2—prostate cancer	7.67e-06	3.31e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PTEN—prostate cancer	7.53e-06	3.24e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—PIK3CA—prostate cancer	7.52e-06	3.24e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—BAD—prostate cancer	7.52e-06	3.24e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MDM2—prostate cancer	7.49e-06	3.23e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ERBB2—prostate cancer	7.39e-06	3.18e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PIK3CB—prostate cancer	7.29e-06	3.14e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—APC—prostate cancer	7.28e-06	3.14e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—INS—prostate cancer	7.27e-06	3.13e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—MTHFR—prostate cancer	7.26e-06	3.13e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PIK3CB—prostate cancer	7.22e-06	3.11e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—EGF—prostate cancer	7.2e-06	3.1e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—IRS1—prostate cancer	7.2e-06	3.1e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—EP300—prostate cancer	7.18e-06	3.09e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PTGS2—prostate cancer	7.16e-06	3.08e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—CREBBP—prostate cancer	7.12e-06	3.07e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PPARA—prostate cancer	7.12e-06	3.07e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CXCL8—prostate cancer	7e-06	3.02e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—GSK3B—prostate cancer	6.99e-06	3.01e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—INS—prostate cancer	6.9e-06	2.97e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CDKN1B—prostate cancer	6.84e-06	2.95e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PIK3CA—prostate cancer	6.83e-06	2.94e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PIK3CD—prostate cancer	6.76e-06	2.91e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CREBBP—prostate cancer	6.75e-06	2.91e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CASP3—prostate cancer	6.7e-06	2.89e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CAV1—prostate cancer	6.7e-06	2.89e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IL2—prostate cancer	6.69e-06	2.88e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—IL6—prostate cancer	6.66e-06	2.87e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CCND1—prostate cancer	6.53e-06	2.81e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CTNNB1—prostate cancer	6.46e-06	2.78e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MAP2K1—prostate cancer	6.45e-06	2.78e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PIK3CD—prostate cancer	6.4e-06	2.76e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.4e-06	2.76e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—NOS3—prostate cancer	6.38e-06	2.75e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MMP9—prostate cancer	6.34e-06	2.73e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—SERPINE1—prostate cancer	6.33e-06	2.73e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CDKN1A—prostate cancer	6.31e-06	2.72e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PTEN—prostate cancer	6.3e-06	2.71e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PTEN—prostate cancer	6.24e-06	2.69e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—AKT1—prostate cancer	6.14e-06	2.65e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—FGF2—prostate cancer	6.13e-06	2.64e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PIK3CG—prostate cancer	6.1e-06	2.63e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—NOS3—prostate cancer	6.05e-06	2.6e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—EP300—prostate cancer	6.01e-06	2.59e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—EP300—prostate cancer	5.95e-06	2.56e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PIK3CB—prostate cancer	5.89e-06	2.54e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—JAK2—prostate cancer	5.88e-06	2.53e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—SRC—prostate cancer	5.84e-06	2.52e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PTGS2—prostate cancer	5.83e-06	2.51e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—INS—prostate cancer	5.77e-06	2.49e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MDM2—prostate cancer	5.74e-06	2.47e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—VEGFA—prostate cancer	5.69e-06	2.45e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—CREBBP—prostate cancer	5.66e-06	2.44e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—ERBB2—prostate cancer	5.66e-06	2.44e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—STAT3—prostate cancer	5.63e-06	2.43e-05	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—AKT1—prostate cancer	5.58e-06	2.4e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PIK3CB—prostate cancer	5.58e-06	2.4e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PIK3CD—prostate cancer	5.36e-06	2.31e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PIK3CA—prostate cancer	5.31e-06	2.29e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CDKN1B—prostate cancer	5.24e-06	2.26e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MYC—prostate cancer	5.23e-06	2.25e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TGFB1—prostate cancer	5.22e-06	2.25e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—EGFR—prostate cancer	5.12e-06	2.21e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PTEN—prostate cancer	5.09e-06	2.19e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—NOS3—prostate cancer	5.06e-06	2.18e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CTNNB1—prostate cancer	4.95e-06	2.13e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—EP300—prostate cancer	4.85e-06	2.09e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—KRAS—prostate cancer	4.84e-06	2.08e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CDKN1A—prostate cancer	4.83e-06	2.08e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PTEN—prostate cancer	4.82e-06	2.08e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PIK3CB—prostate cancer	4.67e-06	2.01e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—EP300—prostate cancer	4.6e-06	1.98e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—SRC—prostate cancer	4.47e-06	1.93e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PIK3CA—prostate cancer	4.44e-06	1.91e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PIK3CA—prostate cancer	4.4e-06	1.9e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—AKT1—prostate cancer	4.34e-06	1.87e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—STAT3—prostate cancer	4.31e-06	1.86e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TP53—prostate cancer	4.3e-06	1.85e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PTEN—prostate cancer	4.04e-06	1.74e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MYC—prostate cancer	4.01e-06	1.73e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TGFB1—prostate cancer	4e-06	1.72e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IL6—prostate cancer	3.93e-06	1.69e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—EGFR—prostate cancer	3.92e-06	1.69e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—EP300—prostate cancer	3.85e-06	1.66e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—KRAS—prostate cancer	3.7e-06	1.6e-05	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—AKT1—prostate cancer	3.63e-06	1.56e-05	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—AKT1—prostate cancer	3.6e-06	1.55e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PIK3CA—prostate cancer	3.59e-06	1.55e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PIK3CA—prostate cancer	3.4e-06	1.47e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—IL6—prostate cancer	3.01e-06	1.3e-05	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—AKT1—prostate cancer	2.93e-06	1.26e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PIK3CA—prostate cancer	2.85e-06	1.23e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—AKT1—prostate cancer	2.78e-06	1.2e-05	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—AKT1—prostate cancer	2.33e-06	1e-05	CbGpPWpGaD
